BioCardia reported sharing its CardiAMP HF II study design at a heart-failure meeting. The filing gives no patient results or change to company plans, so it does not change the outlook.
The filing describes a study plan, not evidence that the treatment helped patients. It gives no patient results or change to BioCardia’s plans, so this report alone does not change how we read the company.
Follow BioCardia, Inc. (BCDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BCDA